The UK and US have finalized a landmark bilateral deal that will preserve zero levies on UK pharmaceutical shipments going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to raise expenditure on pharmaceuticals through the public health system. This commitment secures that import taxes on these crucial exports will stay at zero for a period of three years.
This agreement follows recent statements to dramatically increase duties on branded pharmaceutical imports, with figures discussed up to 100%.
"This deal between the United Kingdom strengthens the global environment for innovative medicines and introduces much-needed balance to American-British medicine commerce," a statement said.
Commercial Impact
Medicines represent one of the the United Kingdom's largest export categories to the America, which is easily the biggest market for large companies like GSK and AstraZeneca.
Export figures indicate that in the year leading up to last September, the UK exported medicines valued at £11.1bn to the US. This figure made up a significant portion of British export trade in that period.
"This guarantee safeguards work, increases funding and facilitates the UK to emerge as a worldwide center for life sciences," a minister commented.
Detailed British Pledges
The deal includes several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to double total NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The percentage drug companies must refund to the NHS to control costs will be restricted at 15%. In the past, rebates topped twenty percent.
Broader Context
This agreement comes amid a long-running tension between the sector and the ministers over medicine costs and NHS adoption.
This friction were heightened by arguments that American patients were paying a premium for the identical medicines than people in the other developed nations.
Recently, several major manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar investments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had declined as a share of its overall budget over the past decade.
